Nanobiotix Logo

Nanobiotix

Develops a first-in-class radioenhancer to amplify radiotherapy's effect directly within tumors.

NANO | PA

Overview

Corporate Details

ISIN(s):
FR0010102145 (+2 more)
LEI:
969500667RSYIH8YL895
Country:
France
Address:
60 RUE DE WATTIGNIES, 75012 PARIS
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Nanobiotix is a late-stage clinical biotechnology company pioneering the development and commercialization of physics-based nanotherapeutics. The company's lead candidate, NBTXR3, is a potential first-in-class radioenhancer designed to be injected directly into a tumor. It works by amplifying the dose and efficacy of radiotherapy within cancer cells, aiming to enhance tumor destruction while sparing surrounding healthy tissue. This approach may also prime an immune response against metastatic tumors. Nanobiotix has a global licensing agreement with Janssen Pharmaceutica NV, a Johnson & Johnson company, to co-develop and commercialize NBTXR3, with an initial focus on head, neck, and lung cancers.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-28 15:41
Major Shareholding Notification
Franchissement de seuil
French 125.2 KB
2025-11-13 18:16
Regulatory News Service
Franchissement de seuil
French 277.7 KB
2025-11-13 17:45
Regulatory News Service
Franchissement de seuil
French 126.3 KB
2025-09-12 19:00
Declaration of Voting Results & Voting Rights Announcements
INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS …
French 112.2 KB
2025-09-12 19:00
Declaration of Voting Results & Voting Rights Announcements
Voting Rights and Shares Capital of the Company
English 113.6 KB
2025-09-02 22:15
Regulatory News Service
Nanobiotix participera à la conférence investisseurs annuelle H.C. Wainwright g…
French 93.9 KB
2025-09-02 22:15
Regulatory News Service
Nanobiotix to Participate in the H.C. Wainwright 27th Annual Global Investment …
English 69.0 KB
2025-08-11 11:29
Major Shareholding Notification
Franchissements de seuils
French 111.3 KB
2025-07-11 11:18
Major Shareholding Notification
Franchissement de seuils
French 123.4 KB
2025-07-11 11:11
Major Shareholding Notification
Franchissement de seuils
French 122.5 KB
2025-06-20 15:17
Major Shareholding Notification
Franchissement de seuils
French 123.1 KB
2025-06-20 15:07
Major Shareholding Notification
Franchissement de seuils
French 123.4 KB
2025-06-10 22:15
Declaration of Voting Results & Voting Rights Announcements
Information mensuelle relative au nombre total de droits de vote et d’actions c…
French 110.8 KB
2025-06-10 22:15
Declaration of Voting Results & Voting Rights Announcements
Voting Rights and Shares Capital of the Company
English 112.0 KB
2025-05-28 08:00
Regulatory News Service
NANOBIOTIX participera à la conférence investisseurs annuelle Jefferies Global …
French 91.4 KB

Automate Your Workflow. Get a real-time feed of all Nanobiotix filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Nanobiotix

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Nanobiotix via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2022-05-11 N/A Other Other 959,060 N/A

Peer Companies

Aprogen, Inc Logo
Develops and manufactures novel biologics and biosimilars for cancer and arthritis treatments.
South Korea
007460
Develops drugs for fibrosis, inflammation, and cancer using NOX inhibitor & CAF modulation tech.
South Korea
293780
Aptahem AB Logo
Develops RNA aptamers to treat acute, life-threatening conditions like sepsis.
Sweden
APTA
Aptamer Sciences Inc Logo
Develops aptamer-based therapeutics and diagnostics for oncology and solid tumors.
South Korea
291650
Aptevo Therapeutics Inc. Logo
Developing multi-specific antibody immunotherapies for hematologic and solid tumor cancers.
United States of America
APVO
Aptorum Group Ltd Logo
Biopharma developing novel therapeutics for oncology, infectious and metabolic diseases.
United States of America
APM
Aquestive Therapeutics, Inc. Logo
Develops oral film drugs for CNS disorders and severe allergies.
United States of America
AQST
Arbutus Biopharma Corp Logo
A clinical-stage virology company developing a functional cure for chronic hepatitis B (HBV).
United States of America
ABUS
Arcellx, Inc. Logo
Engineering controllable cell therapies for cancer and autoimmune diseases.
United States of America
ACLX
Arctic Bioscience Logo
Develops pharma & nutra ingredients from marine lipids for autoimmune & wellness applications.
Norway
ABS

Talk to a Data Expert

Have a question? We'll get back to you promptly.